Studies on the mechanism of resistance to rapamycin in human cancer cells - PubMed (original) (raw)
Studies on the mechanism of resistance to rapamycin in human cancer cells
H Hosoi et al. Mol Pharmacol. 1998 Nov.
Abstract
Rapamycin is a potent cytostatic agent that arrests cells in the G1 phase of the cell cycle. The relationships between cellular sensitivity to rapamycin, drug accumulation, expression of mammalian target of rapamycin (mTOR), and inhibition of growth factor activation of ribosomal p70S6 kinase (p70(S6k)) and dephosphorylation of pH acid stable protein I (eukaryotic initiation factor 4E binding protein) were examined. We show that some cell lines derived from childhood tumors are highly sensitive to growth inhibition by rapamycin, whereas others have high intrinsic resistance (>1000-fold). Accumulation and retention of [14C]rapamycin were similar in sensitive and resistant cells, with all cells examined demonstrating a stable tight binding component. Western analysis showed levels of mTOR were similar in each cell line (<2-fold variation). The activity of p70(S6k), activated downstream of mTOR, was similar in four cell lines (range, 11.75-41. 8 pmol/2 x 10(6) cells/30 min), but activity was equally inhibited in cells that were highly resistant to rapamycin-induced growth arrest. Rapamycin equally inhibited serum-induced phosphorylation of pH acid stable protein I in Rh1 (intrinsically resistant) and sensitive Rh30 cells. In serum-fasted Rh30 and Rh1 cells, the addition of serum rapidly induced c-MYC (protein) levels. Rapamycin blocked induction in Rh30 cells but not in Rh1 cells. Serum-fasted Rh30/rapa10K cells, selected for high level acquired resistance to rapamycin, showed >/=10-fold increased c-MYC compared with Rh30. These results suggest that the ability of rapamycin to inhibit c-MYC induction correlates with intrinsic sensitivity, whereas failure of rapamycin to inhibit induction or overexpression of c-MYC correlates with intrinsic and acquired resistance, respectively.
Similar articles
- Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells.
Hosoi H, Dilling MB, Shikata T, Liu LN, Shu L, Ashmun RA, Germain GS, Abraham RT, Houghton PJ. Hosoi H, et al. Cancer Res. 1999 Feb 15;59(4):886-94. Cancer Res. 1999. PMID: 10029080 - 4E-binding proteins, the suppressors of eukaryotic initiation factor 4E, are down-regulated in cells with acquired or intrinsic resistance to rapamycin.
Dilling MB, Germain GS, Dudkin L, Jayaraman AL, Zhang X, Harwood FC, Houghton PJ. Dilling MB, et al. J Biol Chem. 2002 Apr 19;277(16):13907-17. doi: 10.1074/jbc.M110782200. Epub 2002 Feb 14. J Biol Chem. 2002. PMID: 11847216 - Assessment of cell-signaling pathways in the regulation of mammalian target of rapamycin (mTOR) by amino acids in rat adipocytes.
Pham PT, Heydrick SJ, Fox HL, Kimball SR, Jefferson LS Jr, Lynch CJ. Pham PT, et al. J Cell Biochem. 2000 Sep 7;79(3):427-41. doi: 10.1002/1097-4644(20001201)79:3<427::aid-jcb80>3.0.co;2-0. J Cell Biochem. 2000. PMID: 10972980 - The rapamycin-sensitive signal transduction pathway as a target for cancer therapy.
Hidalgo M, Rowinsky EK. Hidalgo M, et al. Oncogene. 2000 Dec 27;19(56):6680-6. doi: 10.1038/sj.onc.1204091. Oncogene. 2000. PMID: 11426655 Review. - The molecular target of rapamycin (mTOR) as a therapeutic target against cancer.
Mita MM, Mita A, Rowinsky EK. Mita MM, et al. Cancer Biol Ther. 2003 Jul-Aug;2(4 Suppl 1):S169-77. Cancer Biol Ther. 2003. PMID: 14508096 Review.
Cited by
- Rapamycin response in tumorigenic and non-tumorigenic hepatic cell lines.
Jimenez RH, Boylan JM, Lee JS, Francesconi M, Castellani G, Sanders JA, Gruppuso PA. Jimenez RH, et al. PLoS One. 2009 Oct 9;4(10):e7373. doi: 10.1371/journal.pone.0007373. PLoS One. 2009. PMID: 19816606 Free PMC article. - Growth controls connect: interactions between c-myc and the tuberous sclerosis complex-mTOR pathway.
Schmidt EV, Ravitz MJ, Chen L, Lynch M. Schmidt EV, et al. Cell Cycle. 2009 May 1;8(9):1344-51. doi: 10.4161/cc.8.9.8215. Epub 2009 May 18. Cell Cycle. 2009. PMID: 19342893 Free PMC article. Review. - A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt.
Aoki M, Blazek E, Vogt PK. Aoki M, et al. Proc Natl Acad Sci U S A. 2001 Jan 2;98(1):136-41. doi: 10.1073/pnas.98.1.136. Proc Natl Acad Sci U S A. 2001. PMID: 11134523 Free PMC article. - Cytostatic effect of novel mTOR inhibitor, PRP-1 (galarmin) in MDA 231 (ER-) breast carcinoma cell line. PRP-1 inhibits mesenchymal tumors.
Galoian KA, Temple TH, Galoyan A. Galoian KA, et al. Tumour Biol. 2011 Aug;32(4):745-51. doi: 10.1007/s13277-011-0176-3. Epub 2011 Apr 15. Tumour Biol. 2011. PMID: 21494810 - Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumors.
Spunt SL, Grupp SA, Vik TA, Santana VM, Greenblatt DJ, Clancy J, Berkenblit A, Krygowski M, Ananthakrishnan R, Boni JP, Gilbertson RJ. Spunt SL, et al. J Clin Oncol. 2011 Jul 20;29(21):2933-40. doi: 10.1200/JCO.2010.33.4649. Epub 2011 Jun 20. J Clin Oncol. 2011. PMID: 21690471 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous